For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and Attruby represents a genuine change. These groundbreaking therapies protect the transthyretin protein, slowing its harmful build-up and lessening the impact of the c